Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061721 | 0.81 | ADORA2B (0.51) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL1065748 | 0.81 | ADORA2B (0.50) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL1724520 | 0.80 | ADORA2B (0.37) | ADORA1ADORA2BADORA2AADORA3LMNA | |
| SCHEMBL1724800 | 0.80 | ADORA2B (0.42) | ADORA1ADORA2BADORA2AADORA3LMNA | |
| SCHEMBL1724538 | 0.76 | ADORA2B (0.47) | ADORA2B | |
| SCHEMBL21121438 | 0.75 | ADORA2B (0.39) | ADORA1ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL1064077 | 0.73 | MLKL (0.45) | ADORA1ADORA2BADORA2AADORA3LMNA | |
| SCHEMBL24591551 | 0.69 | ADORA2B (0.41) | ADORA1ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL15998426 | 0.69 | ADORA2A (0.32) | ADORA1ADORA2BADORA2AADORA3 | |
| SCHEMBL5546218 | 0.69 | ADORA1 (0.41) | ADORA1ADORA2BADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2405917-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | Advinus Therapeutics Private Limited (IN) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2B 4/4885ADORA2A 1/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2B 4/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.